Antoinette R. Tan, MD, MHSc, discusses the promise of oral selective estrogen receptor degraders as they continue to be developed for the treatment of patients with ER-positive, HER2-negative breast cancer, factors that inform treatment decisions following disease progression on a CDK4/6 inhibitor, and the growing role of antibody-drug conjugates across the breast cancer spectrum.